Cessatech AS
8GN
Company Profile
Business description
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.
Contact
Strandvejen 60
HellerupDK- 2900
DNKT: +45 93872309
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,255.66 | 57.46 | -0.69% |
| DAX 40 | 25,252.99 | 99.40 | -0.39% |
| Dow JONES (US) | 49,387.86 | 54.58 | -0.11% |
| FTSE 100 | 10,228.06 | 10.88 | -0.11% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,575.63 | 45.61 | 0.19% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,949.26 | 4.79 | 0.07% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |